These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1004 related articles for article (PubMed ID: 25734581)

  • 41. Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
    Rödel C; Graeven U; Fietkau R; Hohenberger W; Hothorn T; Arnold D; Hofheinz RD; Ghadimi M; Wolff HA; Lang-Welzenbach M; Raab HR; Wittekind C; Ströbel P; Staib L; Wilhelm M; Grabenbauer GG; Hoffmanns H; Lindemann F; Schlenska-Lange A; Folprecht G; Sauer R; Liersch T;
    Lancet Oncol; 2015 Aug; 16(8):979-89. PubMed ID: 26189067
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Association of Modified-FOLFIRINOX-Regimen-Based Neoadjuvant Therapy with Outcomes of Locally Advanced Pancreatic Cancer in Chinese Population.
    Li X; Guo C; Li Q; Wei S; Zhang Q; Chen Y; Shen Y; Ma T; Li G; Gao S; Que R; Lou J; Yu R; Yuan Y; Wei Q; Huang P; Liang T; Bai X
    Oncologist; 2019 Mar; 24(3):301-e93. PubMed ID: 30459238
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A Phase 1 Study of Stereotactic Body Radiation Therapy Dose Escalation for Borderline Resectable Pancreatic Cancer After Modified FOLFIRINOX (NCT01446458).
    Shaib WL; Hawk N; Cassidy RJ; Chen Z; Zhang C; Brutcher E; Kooby D; Maithel SK; Sarmiento JM; Landry J; El-Rayes BF
    Int J Radiat Oncol Biol Phys; 2016 Oct; 96(2):296-303. PubMed ID: 27475674
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Neoadjuvant FOLFIRINOX in Patients With Borderline Resectable Pancreatic Cancer: A Systematic Review and Patient-Level Meta-Analysis.
    Janssen QP; Buettner S; Suker M; Beumer BR; Addeo P; Bachellier P; Bahary N; Bekaii-Saab T; Bali MA; Besselink MG; Boone BA; Chau I; Clarke S; Dillhoff M; El-Rayes BF; Frakes JM; Grose D; Hosein PJ; Jamieson NB; Javed AA; Khan K; Kim KP; Kim SC; Kim SS; Ko AH; Lacy J; Margonis GA; McCarter MD; McKay CJ; Mellon EA; Moorcraft SY; Okada KI; Paniccia A; Parikh PJ; Peters NA; Rabl H; Samra J; Tinchon C; van Tienhoven G; van Veldhuisen E; Wang-Gillam A; Weiss MJ; Wilmink JW; Yamaue H; Homs MYV; van Eijck CHJ; Katz MHG; Groot Koerkamp B
    J Natl Cancer Inst; 2019 Aug; 111(8):782-794. PubMed ID: 31086963
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Chemotherapy-based split stereotactic body radiation therapy for borderline resectable and locally advanced pancreatic cancer: study protocol of a prospective, single-arm phase II trial.
    Zheng R; Wang C; Huang X; Lin Q; Huang D; Li XB; Huang H; Xu B
    BMJ Open; 2020 Nov; 10(11):e039900. PubMed ID: 33154057
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Survival of patients with resectable pancreatic cancer who received neoadjuvant therapy.
    Christians KK; Heimler JW; George B; Ritch PS; Erickson BA; Johnston F; Tolat PP; Foley WD; Evans DB; Tsai S
    Surgery; 2016 Mar; 159(3):893-900. PubMed ID: 26602840
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Surgery Improves Survival After Neoadjuvant Therapy for Borderline and Locally Advanced Pancreatic Cancer: A Single Institution Experience.
    Rangelova E; Wefer A; Persson S; Valente R; Tanaka K; Orsini N; Segersvärd R; Arnelo U; Del Chiaro M
    Ann Surg; 2021 Mar; 273(3):579-586. PubMed ID: 30946073
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Concurrent Chemoradiotherapy Versus Chemotherapy Alone for Unresectable Locally Advanced Pancreatic Cancer: A Retrospective Cohort Study.
    Choi Y; Oh DY; Kim K; Chie EK; Kim TY; Lee KH; Han SW; Im SA; Kim TY; Ha SW; Bang YJ
    Cancer Res Treat; 2016 Jul; 48(3):1045-55. PubMed ID: 26511805
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Resection of Borderline Resectable and Locally Advanced Pancreatic Adenocarcinomas after Neoadjuvant Chemotherapy.
    Addeo P; Rosso E; Fuchshuber P; Oussoultzoglou E; De Blasi V; Simone G; Belletier C; Dufour P; Bachellier P
    Oncology; 2015; 89(1):37-46. PubMed ID: 25766660
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Continued adjuvant FOLFIRINOX for BRPC or LAPC after neoadjuvant FOLFIRINOX.
    Park J; Kim HY; Na HY; Lee JS; Lee JC; Kim JW; Yoon YS; Hwang JH; Han HS; Kim J
    J Cancer Res Clin Oncol; 2023 May; 149(5):1765-1775. PubMed ID: 35723728
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Preoperative capecitabine and concurrent radiation for borderline resectable pancreatic cancer.
    Stokes JB; Nolan NJ; Stelow EB; Walters DM; Weiss GR; de Lange EE; Rich TA; Adams RB; Bauer TW
    Ann Surg Oncol; 2011 Mar; 18(3):619-27. PubMed ID: 21213060
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Neoadjuvant docetaxel-based chemoradiation for resectable adenocarcinoma of the pancreas: New neoadjuvant regimen was safe and provided an interesting pathologic response.
    Turrini O; Ychou M; Moureau-Zabotto L; Rouanet P; Giovannini M; Moutardier V; Azria D; Delpero JR; Viret F
    Eur J Surg Oncol; 2010 Oct; 36(10):987-92. PubMed ID: 20828979
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Dose escalated concurrent chemo-radiation in borderline resectable and locally advanced pancreatic cancers with tomotherapy based intensity modulated radiotherapy: a phase II study.
    Lewis S; Sastri SC; Arya S; Mehta S; Patil P; Shrivastava S; Phurailatpam R; Shrikhande SV; Engineer R
    J Gastrointest Oncol; 2019 Jun; 10(3):474-482. PubMed ID: 31183197
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Resection of Locally Advanced Pancreatic Cancer without Regression of Arterial Encasement After Modern-Era Neoadjuvant Therapy.
    Kluger MD; Rashid MF; Rosario VL; Schrope BA; Steinman JA; Hecht EM; Chabot JA
    J Gastrointest Surg; 2018 Feb; 22(2):235-241. PubMed ID: 28895032
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Isotoxic high-dose stereotactic body radiotherapy integrated in a total multimodal neoadjuvant strategy for the treatment of localized pancreatic ductal adenocarcinoma.
    Bouchart C; Engelholm JL; Closset J; Navez J; Loi P; Gökburun Y; De Grez T; Mans L; Hendlisz A; Bali MA; Eisendrath P; Van Gestel D; Hein M; Moretti L; Van Laethem JL
    Ther Adv Med Oncol; 2021; 13():17588359211045860. PubMed ID: 34691244
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Chemotherapy versus chemoradiotherapy in borderline resectable and locally advanced pancreatic adenocarcinoma.
    Argalácsová S; Vočka M; Petruželka L; Ryska M; Záruba P; Krška Z; Frýba V; Ulrych J; Černý V; Tůma T; Hoskovec D
    Neoplasma; 2023 Jun; 70(3):468-475. PubMed ID: 37498072
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Focal Radiation Therapy Dose Escalation Improves Overall Survival in Locally Advanced Pancreatic Cancer Patients Receiving Induction Chemotherapy and Consolidative Chemoradiation.
    Krishnan S; Chadha AS; Suh Y; Chen HC; Rao A; Das P; Minsky BD; Mahmood U; Delclos ME; Sawakuchi GO; Beddar S; Katz MH; Fleming JB; Javle MM; Varadhachary GR; Wolff RA; Crane CH
    Int J Radiat Oncol Biol Phys; 2016 Mar; 94(4):755-65. PubMed ID: 26972648
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Stereotactic body radiotherapy for unresected pancreatic cancer: A nationwide review.
    de Geus SWL; Eskander MF; Kasumova GG; Ng SC; Kent TS; Mancias JD; Callery MP; Mahadevan A; Tseng JF
    Cancer; 2017 Nov; 123(21):4158-4167. PubMed ID: 28708929
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Phase 2 multi-institutional trial evaluating gemcitabine and stereotactic body radiotherapy for patients with locally advanced unresectable pancreatic adenocarcinoma.
    Herman JM; Chang DT; Goodman KA; Dholakia AS; Raman SP; Hacker-Prietz A; Iacobuzio-Donahue CA; Griffith ME; Pawlik TM; Pai JS; O'Reilly E; Fisher GA; Wild AT; Rosati LM; Zheng L; Wolfgang CL; Laheru DA; Columbo LA; Sugar EA; Koong AC
    Cancer; 2015 Apr; 121(7):1128-37. PubMed ID: 25538019
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Tolerability and Long-term Outcomes of Dose-Painted Neoadjuvant Chemoradiation to Regions of Vessel Involvement in Borderline or Locally Advanced Pancreatic Cancer.
    Wo JY; Niemierko A; Ryan DP; Blaszkowsky LS; Clark JW; Kwak EL; Lillemoe KD; Drapek LN; Zhu AX; Allen JN; Faris JE; Murphy JE; Nipp R; Fernandez-Del Castillo C; Ferrone CR; Hong TS
    Am J Clin Oncol; 2018 Jul; 41(7):656-661. PubMed ID: 28134673
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 51.